Aberrant expression of miR-133a in endothelial cells inhibits angiogenesis by reducing pro-angiogenic but increasing anti-angiogenic gene expression.

Autor: Ahmed S; Cardiovascular Molecular Pharmacology Laboratory, Research Institute in Healthcare Science, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1SB, UK., Kurusamy S; Cardiovascular Molecular Pharmacology Laboratory, Research Institute in Healthcare Science, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1SB, UK.; Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK., David ELS; Cardiovascular Molecular Pharmacology Laboratory, Research Institute in Healthcare Science, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1SB, UK., Khan K; Cardiovascular Molecular Pharmacology Laboratory, Research Institute in Healthcare Science, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1SB, UK., Kalyanakrishnan K; Cardiovascular Molecular Pharmacology Laboratory, Research Institute in Healthcare Science, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1SB, UK., Ian-Gobo M; Cardiovascular Molecular Pharmacology Laboratory, Research Institute in Healthcare Science, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1SB, UK., Kola TM; Cardiovascular Molecular Pharmacology Laboratory, Research Institute in Healthcare Science, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1SB, UK., Wilkinson RN; School of Life Sciences, Medical School, Queens Medical Centre, University of Nottingham, Nottingham, UK., Kannappan V; Experimental Cancer Therapeutics Group, Research Institute in Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK., Wang W; Experimental Cancer Therapeutics Group, Research Institute in Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK., Gómez MJ; Unidad de Bioinformática, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain., Redondo JM; Gene Regulation in Cardiovascular Remodelling and Inflammation Group, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain., Cotton J; Cardiovascular Molecular Pharmacology Laboratory, Research Institute in Healthcare Science, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1SB, UK. jamescotton@nhs.net.; Department of Cardiology, Heart and Lung Centre, New Cross Hospital, Wolverhampton, UK. jamescotton@nhs.net., Armesilla AL; Cardiovascular Molecular Pharmacology Laboratory, Research Institute in Healthcare Science, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1SB, UK. A.Armesilla@wlv.ac.uk.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. A.Armesilla@wlv.ac.uk.

Publikováno v: Scientific reports [Sci Rep] 2022 Aug 30; Vol. 12 (1), pp. 14730. Date of Electronic Publication: 2022 Aug 30.